Safety of Gadovist® in Renally Impaired Patients

Update Il y a 4 ans
Reference: EUCTR2008-004496-22

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to assess the magnitude of potential risk with the administration of Gadovist in patients with moderate to severe renal impairment for the development of NSF, based on diagnostically specific clinical and histopathological information.


Inclusion criteria

  • Patients with moderate to severe renal impairment